Leadership Team

Mark Andersen

Mark Andersen, CPA, CFA

Chief Financial Officer, Vice President of Administration

Mark Andersen

Mark Andersen, CPA, CFA

Chief Financial Officer, Vice President of Administration

Mark Andersen, CFA and CPA, most recently served as Vice President Finance and Corporate Controller for a biomedical company in Georgia. In that role, he was responsible for SEC reporting, mergers and acquisitions valuations and diligence, accounts payable, payroll, controls, and the employee retirement plan.

Previously, Andersen held multiple financial leadership roles at Eli Lilly and Company, including Investments Director for the company’s pension plan, where he managed highly diversified investment portfolios totaling approximately $13 billion in assets. He also served as Finance Director for Mergers & Acquisitions, where he completed acquisitions of both domestic and international businesses, and provided financial leadership and negotiation support for licensing and business development transactions. As Finance Director and Controller for Lilly USA, Andersen led the financial planning and analysis team of Lilly's U.S. sales and marketing affiliate with more than $10 billion in annual sales, and served as its financial controller with oversight for accounting and internal controls. He started his career in public accounting as an auditor with firms KPMG and Deloitte.

Andersen received his Bachelor of Science degree in accounting and Master of Science in accountancy from Southern Utah University, graduating magna cum laude and with high distinction. He earned his MBA from the University of Michigan Ross School of Business.

Robert Considine, PhD

Robert Considine, PhD

Administrative Director, IBRI Diabetes Center

Robert Considine, PhD

Robert Considine, PhD

Administrative Director, IBRI Diabetes Center

Robert V. Considine, PhD, joined the Division of Endocrinology at the Indiana University School of Medicine in Indianapolis, Ind., as an Assistant Professor in 1997 and was promoted to Professor in 2013. Prior to his appointment at the IU School of Medicine, he was on the faculty of the Department of Medicine at Thomas Jefferson University in Philadelphia, Pa., where he had completed his doctoral training.

Dr. Considine’s research is focused on understanding the contribution of obesity to the development of diabetes and its complications. In early work, his lab made seminal observations about the function of the adipose tissue hormone leptin in humans.  More recently, the Considine Lab has focused on the effects of bariatric surgery to alter gut hormone release and improve glucose homeostasis and insulin sensitivity.  In collaboration with David Kareken, PhD, at the IU School of Medicine, Dr. Considine is also utilizing neuroimaging techniques to understand the reward system response to food cues in human subjects.  

Dr. Considine is currently the Associate Director of the National Institutes of Health (NIH)-funded Diabetes Center at the IU School of Medicine, and oversees the Analyte Laboratory, which provides quantitation of adipokines, cytokines, gut peptides and hormones from human and animal samples.  He is also the Statewide Director for Endocrine and Reproductive Biology, a second-year course in the IU School of Medicine curriculum. 

Decio Eizirik, MD, PhD

Decio Eizirik, MD, PhD

Scientific Director, IBRI Diabetes Center

Decio Eizirik, MD, PhD

Decio Eizirik, MD, PhD

Scientific Director, IBRI Diabetes Center

Dr. Eizirik is a Professor at the Université Libre de Bruxelles (ULB) Center for Diabetes Research, Brussels, Belgium, and a member of the ULB medical faculty. He is also an Investigator for the Indiana Biosciences Research Institute (IBRI) and Scientific Director of the IBRI Diabetes Center.

He has published more than 370 full papers and reviews in peer-reviewed international journals and has received several national and international prizes, including the Juvenile Diabetes Research Foundation (JDRF) Diabetes Care Research Award in 1998; the “2012 Albert Renold Prize Lecture for Outstanding Achievements in Research on the Islets of Langerhans” awarded by the European Association for the Study of Diabetes (EASD) in 2012, and the “2013 Rumbough Award for outstanding achievements in type 1 diabetes research” awarded by the JDRF.

Dr. Eizirik is listed by the ISI Essential Science Indicators among the 1 percent most cited scientists in Clinical Medicine and Biology & Biochemistry, with an h-index of 81. He has served as Honorary (Scientific) Secretary of the EASD and as Deputy Editor of Diabetologia, the official journal of the EASD. His research focuses on the molecular mechanisms regulating insulitis and beta cell apoptosis in type 1 diabetes, pancreatic beta cell imaging, generation of beta cells from inducible pluripotent cells and on the search for novel approaches to prevent the progressive loss of beta cell mass in diabetes.

Stephanie Grinage

Stephanie Grinage, MHA

Vice President for Advancement

Stephanie Grinage

Stephanie Grinage, MHA

Vice President for Advancement

Stephanie Grinage joined the Indiana Biosciences Research Institute (IBRI) as vice president for Advancement in June 2018. She serves as the primary strategic partner in cultivating and maintaining new and existing relationships with major donors and oversees and manages all aspects of IBRI’s fundraising programs.

Prior to IBRI she served as associate vice chancellor for Medical Advancement and associate dean for the University of Illinois at Chicago (UIC) College of Medicine where she directed all advancement activities across the College of Medicine campuses to maximize private philanthropy. Prior to UIC, she served in fundraising positions as KU Endowment’s vice president for Medical Development supporting the University of Kansas Medical Center; associate vice president for the University of South Florida/USF Health, and in leadership development positions with Arizona State University and Wichita State University.

Stephanie is a veteran of three significant endowment campaigns: the $1 billion Campaign Illinois initiative, the Campaign for Leadership at Arizona State University, and the $1.2 billion, “Far Above: The Campaign for Kansas”. During her tenure at KU Endowment, she was a member of the team that created the KU Institute for Advancing Medical Innovation, a model for philanthropy, industry and academia to collaborate in advancing university innovations in the life sciences. Most recently, she was instrumental in launching the $750 million IGNITE campaign for UIC.

She earned her Master's of Health Administration (MHA) from the University of Illinois-Chicago and received her Bachelor of Arts degree in communications from Fort Hays State University in Hays, Kan. She also attended Arizona State University in Tempe, Ariz.

Jay McGill

Jay McGill, PhD

Chief Operating Officer

Jay McGill

Jay McGill, PhD

Chief Operating Officer

Jay McGill, PhD is Indiana Bioscience Research Institute's Chief Operating Officer (COO). Dr. McGill brings a strong background of industrial experience, operations, and working in innovation across the industrial-academic boundaries. Most recently, Dr. McGill served as senior Director at Eli Lilly and Company in Lilly Research Laboratories responsible for science and technology partnerships. In this role, Dr. McGill served as the interface between academic institutions and Lilly Research Labs as well as overseeing Lilly's portfolio of research-based public/private partnerships and consortium participation.

In 2012-2014, Dr. McGill was on assignment as a loaned executive with BioCrossroads where he held the title of Translational Scientific Officer. His responsibilities at BioCrossroads included the support of several initiatives at the Indiana Clinical and Translational Institute (Indiana CTSI) at the Indiana University School of Medicine. He also provided support in the creation of the Indiana Biosciences Research Institute. Dr. McGill also was instrumental in establishing the Indiana CTSI–Covance partnership for a Phase 1 Clinic within IU Hospital and played a critical role in creating the Strategic Pharma-Academic Research Consortium for Translational Medicine (SPARC). Dr. McGill served as the Chief Operations Officer and Treasurer for the Fairbanks Institute for Healthy Communities.

Previous to his assignment at BioCrossroads, Dr. McGill was the Senior Director of Research Business Operations where his responsibilities included oversight and management of all research-based (preclinical) collaborations, alliances, and outsourcing partners, including chemistry, in vitro and in vivo biology, preclinical ADME and toxicology. Dr. McGill also was responsible for the research quality and compliance organizations. From December 2010 to June 2012, he served as Interim COO of the Lilly China Research Development Center (LCRDC) in Shanghai, China. After Eli Lilly announced its intentions to create a research and development site in China, Dr. McGill led a team to identify a location, construct the facility and establish the operations for LCRDC, which opened in June 2012.

After receiving a Bachelor of Science degree in chemistry from the University of Georgia and a PhD in organic chemistry from Indiana University, Dr. McGill joined Eli Lilly and Company in 1990 as a Senior Scientist in the Chemical Process Development Group. In 1998, he joined the Discovery Chemistry Research and Technologies organization and held a number of positions including Head of the Custom Synthesis Lab, Director of the Discovery Chemistry Synthesis Group, Sr. Director – Global Chemistry Sourcing. In 2008, as part of reorganization within Lilly Research Laboratories, all of the research-based sourcing groups (chemistry, in vitro and in vivo biology, toxicology and ADME) were consolidated under Dr. McGill’s leadership as Senior Director, External Research Operations.

Dr. McGill has more than 25 years of experience in pharmaceutical research and development, research collaborations, and outsourcing management. He has been instrumental in creating and developing Eli Lilly’s collaborations in Asia and establishing operations to support an external network of research-based outsourcing partners and alliances. Dr. McGill is known for his leadership in the pioneering of novel and transformational partnership models.

Alan Palkowitz, PhD

Alan Palkowitz, PhD

President & CEO

Alan Palkowitz, PhD

Alan Palkowitz, PhD

President & CEO

Alan Palkowitz, PhD, started his career as the Indiana Bioscience Research Institute’s (IBRI) President and CEO in September 2020. Dr. Palkowitz has 30 years of experience in drug discovery and development in both industry and academia. He is passionate about translational research and is driven to build a world-class organization that catalyzes activities across the life sciences ecosystem.

In addition to his role at the IBRI, Dr. Palkowitz maintains his roles at the Indiana University (IU) School of Medicine as a senior research professor of medicine, where he directs the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center, and is a key contributor to the IU Precision Health Initiative’s chemical biology and biotherapeutics scientific pillar. The chemical biology and biotherapeutics scientific pillar seeks to better understand the cellular processes behind abnormal gene and protein activity to improve scientists’ ability to identify drug targets and develop precision therapeutics.

Prior to joining the faculty at the IU School of Medicine, Dr. Palkowitz served as the vice president of Discovery Chemistry Research and Technologies at Eli Lilly and Company, where he worked for 28 years. In his role as vice president, Dr. Palkowitz was responsible for the global small molecule drug discovery strategy and delivery of clinical candidates in disease areas including cancer, diabetes, immunology, pain and neurodegenerative disorders.

Additionally, Dr. Palkowitz has served on several prominent advisory committees, including most recently the National Institutes of Health's National Center for Advancing Translational Sciences Advisory Council and the National Academies of Sciences’ Board on Chemical Sciences and Technology. He has published numerous research articles and is an inventor on almost 60 US patents. Dr. Palkowitz obtained his PhD in synthetic organic chemistry from the Massachusetts Institute of Technology and his bachelor’s degree in chemistry from the University of California at Berkeley.

Michael Pugia

Michael Pugia, PhD

Investigator and Director, Bioanalytical Technologies

Michael Pugia

Michael Pugia, PhD

Investigator and Director, Bioanalytical Technologies

Michael Pugia, PhD, is an Investigator and Director of the Indiana Biosciences Research Institute's (IBRI) Bioanalytical Technologies group, effective May 2019. Before that, he served as Director of the IBRI’s Single Cell Analytics Center leading the efforts to develop new single-cell bioanalytical technology for measuring proteomic biomarkers as targeted diagnostics for the fields of endocrinology, oncology and infectious disease.

Prior to joining the IBRI, Michael spent 30 years in the biomedical in-vitro diagnostic industry for the Bayer and then Siemens diagnostic divisions. In his roles at Bayer and Siemens he contributed to 21 new product launches that have since produced more than 25 billion test results worldwide. Some of the products also helped to establish new, cost effective healthcare programs, such as Japan’s use of microalbumin/creatinine ratio for annual mass screening of all children for kidney disease.

He spent 15 of those 30 years as a director of research and development working on new systems and methods for point of care (POC) diagnostics and hospital laboratories. Additionally, he spent 20 years leading next generation analytical and diagnostic technology research teams in collaboration with leading design house, health care institutions, universities and technology companies around the world. In his last eight years, he served as a principle key expert for Siemens’ Healthcare sector in Strategic Innovations and lead the Siemens’ contribution to the EU IMI CANCER ID program by placing the Circulating Tumor Cell platform into leading EU cancer centers and the U.S. Siemens CLIA lab for clinical research use.

For his entire career, Michael’s primary biochemistry research interest for clinical diagnostics has been identifying immunity markers for infections in diabetes and co-morbidities.

In 2009, Michael was honored with the Siemens Inventor of the Year award for his pioneering work on the miniaturization of “lab-on-a-chip” diagnostic tools for POC testing. He also was recognized with nine Bayer Science and Technology Awards including the Outstanding Bayer Technology Award, the Bayer Corporate Quality Excellence Award and the Near Patient Testing Segment General Manager Award for Exceptional Leadership for his contributions to the CLINITEK and MULTISTIX urinalysis product lines. 

The American Association of Clinical Chemistry celebrated him as the Samuel Natelson Senior Investigator in recognition of outstanding service for the advancement of clinical chemistry and as the winner of the 1st Annual AI Free Memorial Lectureship.

Michael holds 60 allowed US patents and has 72 pending US patent applications yielding more than 500 worldwide patent filings. He also has more than 60 peer review publications, 15 book chapters and hundreds of conference papers and lectures in a wide variety of chemistry disciplines to his name. He earned his PhD in chemistry from Texas Tech University and his bachelor’s degree in chemistry from Clarkson University.

While working in industry, Michael has held pro-bono adjunct positions as a Visiting Scholar at the University of Notre Dame and as a Clinical Research Professor at the University of Louisville Medical School to pursue his research into the causes of inflammation during kidney disease and diabetes.

Daniel Robertson

Daniel Robertson, PhD

Investigator and Director, Applied Data Sciences Center

Daniel Robertson

Daniel Robertson, PhD

Investigator and Director, Applied Data Sciences Center

Daniel H. Robertson, a proven and experienced technical leader in information technology (IT), computational science and research, is focused on defining and developing the Institute’s computational analytics, digital and data science capabilities.

Dr. Robertson originally joined the IBRI in mid-2015 as part of a loaned executive program at Eli Lilly and Company, but in mid-2017 he accepted a permanent position at the IBRI due to the opportunity at the IBRI to drive innovative research among multiple life sciences companies, academic institutions and technology companies to advance solutions to critical problems.

His most recent role at Eli Lilly and Company was Senior Director of Research IT where he led the IT team supporting discovery systems and processes across six global research sites and nine functional/therapeutic areas. During his leadership role in IT at Lilly, Dr. Robertson restructured Research IT to become a leaner, more efficient organization, reset the Research IT strategy supporting the discovery functions, delivered emerging new technology and analyses through informatics, enhanced support for HPC, cloud, and internal big data storage and analysis. He also transformed the IT support for Open Innovation Drug Discovery program to be the first high-performing DevOps team, which was recognized with an InformationWeek 500 award. Throughout his 10 years in leadership roles at Lilly, Dr. Robertson developed several individuals within his organization to advance to higher level roles in other organizations within Lilly. He joined Lilly as a research scientist in Lilly Research Laboratories and performed numerous independent contributor and scientific leadership roles before transitioning to the IT organization in 2010.

Dr. Robertson earned his PhD in physical chemistry from Florida State University and his Bachelor of Science degree in chemistry, graduating Summa Cum Laude, from Florida Southern College. After earning his PhD., Dr. Robertson served as an NRC/NRL Postdoctoral Research Associate at the Naval Research Laboratory in Washington, D.C., and then held several positions at Indiana University-Purdue University Indianapolis (IUPUI) from 1993 through 2000. He last served as Associate Scientist and Director of Technical and Administrative Services and Manager of the Facility for Computational Molecular Science at IUPUI before joining Eli Lilly and Company in 2000.

Dr. Robertson has published 67 papers in refereed journals, authored three invited book chapters, and conducted more than 65 professional/technical presentations. He has been honored with multiple awards from Eli Lilly and Company and IUPUI, and is a member of the American Chemical Society, American Physical Society and physics and mathematics honoraries.

View publications

 

Applied Data Sciences Center

Focusing on the creation of tools and development of applications that will enable deep computer learning to assist researchers, clinicians, and patients.

Learn more

Vidadi Yusibov

Vidadi Yusibov, PhD

Research Program Director, Pharmaceutical Biotechnology Center

Vidadi Yusibov

Vidadi Yusibov, PhD

Research Program Director, Pharmaceutical Biotechnology Center

Vidadi Yusibov, Ph.D., is a science-focused executive with more than 15 years of operational and strategic leadership experience in biopharmaceutical R&D and business development, with particular focus on vaccines and therapeutics. At IBRI, his responsibilities will include expanding and strengthening IBRI’s core capabilities in Pharmaceutical Biotechnology through building and managing a cross-functional matrix organization, developing translational research programs and establishing partnerships.

Prior to joining the IBRI he was the Scientific Director and then the Executive Director of the Fraunhofer USA Center for Molecular Biotechnology where he developed strategic plans and led the growth of a unique translational research organization, secured more than $150 million from public and private institutions. He established multiple partnerships involving academia, industry and federal institutions. Furthermore, Dr. Yusibov worked extensively with local and federal legislators, economic development authorities and agencies to better align developments at the Center with regulatory guidelines and market needs.

In his academic career, Dr. Yusibov was an Assistant Professor at Thomas Jefferson University in Philadelphia after holding research positions at Purdue University in Lafayette, Indiana. His research has focused on the development and application of new technologies for vaccine and therapeutics development.

He earned his Ph.D. in Molecular Biology at the Academy of Sciences in Moscow, Russia and his M.S. in Plant Biochemistry and his B.A. in Biology at St. Petersburg University in St. Petersburg, Russia. As the developer of new technology for human health applications, he initiated and led a conference series known as “New Technologies, New Vaccines” that became a place for the exchange of new knowledge and ideas for the scientific community and regulatory authorities.